Welcome to our dedicated page for Glaukos SEC filings (Ticker: GKOS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Glaukos Corporation (GKOS) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, with AI-powered tools to help interpret the information. Glaukos is an ophthalmic pharmaceutical and medical technology company focused on therapies for glaucoma, corneal disorders, and retinal diseases, and its filings provide detailed insight into this business.
Through periodic reports such as Forms 10-Q and 10-K, investors can review Glaukos’ net sales, segment performance in glaucoma and corneal health, gross margins, operating expenses, and net income or loss. These filings also describe risk factors relevant to its ophthalmic device and pharmaceutical portfolio, including regulatory requirements, clinical trial processes, reimbursement dynamics, manufacturing considerations, and intellectual property matters referenced in the company’s public communications.
Current reports on Form 8-K capture material events such as quarterly and annual financial results, preliminary net sales updates, and investor presentations. For example, Glaukos has filed 8-Ks to furnish press releases on second and third quarter financial results, preliminary unaudited net sales for a fiscal year, and investor presentation materials. These documents often include or reference revenue guidance ranges and explanations of non-GAAP financial measures and constant currency net sales metrics.
On Stock Titan, AI-generated summaries help explain the key points of lengthy filings, highlighting items such as revenue trends, segment details, and notable risk disclosures without replacing the full text. Real-time updates from EDGAR ensure new Glaukos filings appear promptly, while dedicated sections make it straightforward to locate quarterly reports, annual reports, and current reports tied to material announcements.
For users analyzing GKOS, this page offers a structured view of Glaukos’ SEC reporting history alongside AI insights that clarify complex financial and regulatory information related to its ophthalmic pharmaceutical and medical technology activities.
Glaukos Corp Chairman and CEO Thomas William Burns reported multiple equity compensation awards tied to performance goals. He received stock options covering 18,933 shares of common stock at an exercise price of $55.18 per share and 110,254 shares at $48.46 per share, reflecting portions of earlier performance-based grants that were earned after the board determined certain operational targets were achieved on March 25, 2026. He was also granted a new option for 98,474 shares at an exercise price of $109.60 per share, which vests over four years. In addition, he acquired 9,380 and 14,184 shares of common stock from performance-based restricted stock unit awards, with specified vesting in March and December 2026. Following these awards, he holds 263,271 common shares directly and maintains significant indirect holdings through various Burns family trusts.
Glaukos Corp SVP & CFO Alex R. Thurman reported a mix of equity awards and a small share sale. He sold 2,511 shares of common stock at $106.46 per share under a pre-arranged Rule 10b5-1 trading plan adopted on December 15, 2025. He received stock options for 8,228 shares at an exercise price of $55.18 expiring in 2032 and 20,515 shares at $109.60 expiring in 2036, along with other performance-based option portions that became earned after operational targets were achieved. He also acquired 3,303 shares of common stock from a performance-based restricted stock unit award. Following these transactions, he directly owns 45,270 shares of common stock, including unvested restricted stock units, indicating the sale is small relative to his overall equity position.
GLAUKOS Corp President & COO Joseph E. Gilliam reported a series of equity awards on March 25, 2026. He received stock options covering 16,462 and 21,955 shares of common stock at an exercise price of $55.18 per share and an additional option for 36,751 shares at $48.46 per share. He also was granted 5,829 and 17,792 shares of common stock as restricted stock unit-based awards. According to the footnotes, these grants were tied to the company’s achievement of multi-year operational and performance targets, with portions vesting in March and December 2026 and others vesting 25% annually over four years. These are compensation-related grants rather than open-market trades.
GLAUKOS Corp chief development officer Tomas Navratil reported several stock awards of common shares on March 25, 2026. The Form 4 shows multiple acquisitions coded as grants, with no purchase price, tied to previously granted restricted stock unit (RSU) awards.
These shares were earned after the board’s Compensation, Nominating and Governance Committee determined that specified multi-year operational performance targets from 2022, 2023, and 2024 RSU grants had been achieved. Following the latest grant entry, Navratil directly holds 101,238 common shares, and the footnotes state he also holds additional unvested RSUs, including 57,486 units that have not yet vested or been delivered.
Glaukos Corp ownership disclosure: The Vanguard Group filed an amendment on 03/13/2026 reporting 0 shares beneficially owned and 0% of the class following an internal realignment and separate reporting by subsidiaries.
The amendment states Vanguard subsidiaries will report beneficial ownership on a "disaggregated basis" in accordance with SEC Release No. 34-39538 (January 12, 1998). The filing is signed by Ashley Grim, Head of Global Fund Administration, dated 03/26/2026.
Glaukos Corp Chairman and CEO Thomas William Burns reported a tax-withholding share disposition related to equity compensation. On the vesting of previously granted restricted stock units, 2,744 shares of common stock were withheld by the company at $105.23 per share to cover his tax obligations. After this non-market transaction, he directly holds 239,707 common shares and also reports indirect ownership through several Burns family trusts. The filing also notes 59,399 restricted stock units that remain unvested and undelivered.
Glaukos Corp Chief Development Officer Tomas Navratil reported routine tax-related share withholdings tied to restricted stock unit vesting. On March 23, 2026, 2,628 shares of common stock were withheld at $106.84 per share, leaving 71,003 shares directly held. On March 24, 2026, an additional 2,546 shares were withheld at $105.23 per share, leaving 68,457 shares directly held. These dispositions were made to satisfy tax withholding obligations on previously granted restricted stock units rather than as open-market sales. Footnotes state his holdings include 29,840 and 24,705 restricted stock units from prior grants that have not yet vested or been delivered.
Glaukos Corp Senior Vice President and Chief Financial Officer Alex R. Thurman reported recent stock transactions. On March 24, he sold 1,521 shares of common stock in an open-market trade at an average price of $105.24 per share under a pre-arranged Rule 10b5-1 trading plan adopted on December 15, 2025. Following these transactions, he directly holds 44,478 shares of common stock, and his holdings also include restricted stock units that have not yet vested or been delivered, as described in the footnotes. Additional dispositions of 2,020 shares on March 24 and 1,230 shares on March 23 were shares withheld by the company to cover tax obligations upon vesting of restricted stock units granted in 2023 and 2022.
GLAUKOS Corp president and COO Joseph E. Gilliam reported routine share dispositions tied to tax withholding, not open-market sales. On March 23 and 24, 2026, a total of 15,118 shares of common stock were withheld by the company to cover his tax obligations upon restricted stock unit vesting. Following these transactions, he continues to hold 72,540 shares of common stock directly. Footnotes indicate his holdings also include unvested restricted stock units from prior grants.
GKOS reports a proposed sale of 2,511 shares of Common Stock tied to a restricted stock vesting on 03/24/2026. The filing lists the sale as Compensation and shows prior dispositions of 625 shares on 03/17/2026 and 1,521 shares on 03/24/2026.